Last update 21 Jun 2025

SSGJ-705

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
705, SSGJ 705, SSGJ-705
+ [1]
Target
HER2 x PD-1
Action
antagonists, inhibitors
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases
Active Indication
Advanced Malignant Solid NeoplasmHER2 Positive Solid TumorsAdvanced cancer+ [2]
Inactive Indication-
Originator Organization
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Active Organization
Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Inactive Organization-
License Organization
Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd.
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with SSGJ-705
NCT07022002
/ Not yet recruitingPhase 2
A Phase II Study to Evaluate the Safety and Efficacy of SSGJ-705 Monotherapy and Combination Therapy in Patients With Advanced HER2-Expressing Solid Tumors
NCT06390774
/ RecruitingPhase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors
NCT05145179
/ Unknown statusPhase 1
A Phase I, Multicenter, Open-Label, First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors
100 Clinical Results associated with SSGJ-705
Login to view more data
100 Translational Medicine associated with SSGJ-705
Login to view more data
100 Patents (Medical) associated with SSGJ-705
Login to view more data
100 Deals associated with SSGJ-705
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
China
Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.
30 Jun 2025
HER2 Positive Solid TumorsPhase 2
China
Shenyang Sunshine Pharmaceuticals Co., Ltd.Shenyang Sunshine Pharmaceuticals Co., Ltd.
19 Jun 2025
Advanced cancerPhase 1
China
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
15 Apr 2024
Metastatic breast cancerPhase 1-
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
-
Stomach CancerPhase 1-
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
-
Solid tumorIND Approval
China
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
29 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free